The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Northern District of California on behalf of shareholders of Vaxart, Inc. who purchased shares between June 25, 2020 and July 25, 2020.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) Vaxart exaggerated the prospects of its COVID-19 vaccine candidate, including its purported role or involvement in Operation Warp Speed ('OWS'), a program which commits the federal government to massive funding for the development of COVID-19 vaccines; 2) Vaxart's COVID-19 vaccine candidate had no reasonable prospect for mass production and marketing and was not among the companies chosen to receive significant financial support from OWS to produce hundreds of millions of vaccine doses; and 3) Vaxart's COVID-19 vaccine candidate was merely selected to participate in preliminary U.S. government studies to determine potential areas for possible OWS partnership and support.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until October 23, 2020 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.